Warning
This is an unofficial archive of PsychonautWiki as of 2025-08-08T03:33:20Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.

Talk:Huperzine A: Difference between revisions

From PsychonautWiki Archive
Jump to navigation Jump to search
← Older edit
>Yzgzs
m Grammatics
>AxeOvKindness
m said mg instead of ug
 
(34 intermediate revisions by 2 users not shown)
Line 50: Line 50:


     <!-- Nomenclature -->
     <!-- Nomenclature -->
     |NameCommon=[[common name::Huperzine A]]
     |NameCommon=[[common name::Huperzine A、HupA]]
     |NameSubstitution=N,N-Dimethyltryptamine
     |NameSubstitution=Huperzine A
     |NameSystematic=[[systematic name::2-(1H-Indol-3-yl)-N,N-dimethylethanamine]] <!-- Use IUPAC naming convention -->
     |NameSystematic=[[systematic name::5,9-Methanocycloocta[b]pyridin-2(1H)-one, 5-amino-11-ethylidene-5,6,9,10-tetrahydro-7-methyl-, (5R,9R,11E)-]] <!-- Use IUPAC naming convention -->


     <!-- Class Membership -->
     <!-- Class Membership -->
     |EffectClass=[[psychoactive class::Nootropic]] / [[psychoactive class::Oneirogen]]
     |EffectClass=[[psychoactive class::Nootropic]] / [[psychoactive class::Oneirogen]]
     |ChemicalClass=[[chemical class::Tryptamine]]
     |ChemicalClass=[[chemical class::Others]]


     <!-- Dosage/Duration per ROA -->
     <!-- Dosage/Duration per ROA -->
Line 63: Line 63:
     |OralROA_Collapsed=false
     |OralROA_Collapsed=false
     |OralROA_Caption=
     |OralROA_Caption=
     |OralROA_Bioavailability=[[Oral min bioavailability::x]]% - [[Oral max bioavailability::y]]%<ref>APA formatted citation.</ref> <!-- Refer to this tool to generate APA citations from DOI links: https://reftag.appspot.com/doiweb.py -->
     |OralROA_Bioavailability=[[Oral min bioavailability::96]]% - [[Oral max bioavailability::100]]%{{citation needed}}
     |OralROA_Microdose=
     |OralROA_Microdose=
     |OralROA_Threshold=[[Oral threshold dose::25]] [[Oral dose units::ug]]  
     |OralROA_Threshold=[[Oral threshold dose::25]] [[Oral dose units::ug]]  
     |OralROA_Light=[[Oral min light dose::25]] - [[Oral max light dose::50]] ug
     |OralROA_Light=[[Oral min light dose::50]] - [[Oral max light dose::100]] ug
     |OralROA_Common=[[Oral min common dose::50]] - [[Oral max common dose::200]] ug
     |OralROA_Common=[[Oral min common dose::100]] - [[Oral max common dose::200]] ug
     |OralROA_Strong=[[Oral min strong dose::200]] - [[Oral max strong dose::450]] ug
     |OralROA_Strong=[[Oral min strong dose::200]] - [[Oral max strong dose::450]] ug
     |OralROA_Heavy=[[Oral heavy dose::450]] mg +
     |OralROA_Heavy=[[Oral heavy dose::450]] ug +
     |OralROA_TimelineFile=
     |OralROA_TimelineFile=
     |OralROA_TimelineWidth=
     |OralROA_TimelineWidth=
Line 75: Line 75:
     |OralROA_Onset=[[Oral min onset time::x]] - [[Oral max onset time::y]] [[Oral onset time units::minutes]]
     |OralROA_Onset=[[Oral min onset time::x]] - [[Oral max onset time::y]] [[Oral onset time units::minutes]]
     |OralROA_Comeup=[[Oral min comeup time::x]] - [[Oral max comeup time::y]] [[Oral comeup time units::minutes]]
     |OralROA_Comeup=[[Oral min comeup time::x]] - [[Oral max comeup time::y]] [[Oral comeup time units::minutes]]
     |OralROA_Peak=[[Oral min peak time::x]] - [[Oral max peak time::y]] [[Oral peak time units::hours]]
     |OralROA_Peak=[[Oral min peak time::10]] - [[Oral max peak time::30]] [[Oral peak time units::minutes]]<ref>[http://www.example.org 链接文本]，附加文本。</ref>
     |OralROA_Offset=[[Oral min offset time::x]] - [[Oral max offset time::y]] [[Oral offset time units::hours]]
     |OralROA_Offset=[[Oral min offset time::x]] - [[Oral max offset time::y]] [[Oral offset time units::hours]]
     |OralROA_Aftereffects=[[Oral min afterglow time::x]] - [[Oral max afterglow time::y]] [[Oral afterglow time units::hours]]
     |OralROA_Aftereffects=[[Oral min afterglow time::x]] - [[Oral max afterglow time::y]] [[Oral afterglow time units::hours]]
Line 333: Line 333:
*'''[[UncertainInteraction::Acetylcholinesterase inhibitors]]''' - Huperzine A may result in a cholinergic crisis when combined with other potent acetylcholinesterase inhibitors. Caution should also be exercised when combining Huperzine  
*'''[[UncertainInteraction::Acetylcholinesterase inhibitors]]''' - Huperzine A may result in a cholinergic crisis when combined with other potent acetylcholinesterase inhibitors. Caution should also be exercised when combining Huperzine  
A with caffeine or nicotine.
A with caffeine or nicotine.
*'''[[UncertainInteraction::Dissociatives]]''' -  
*'''[[UncertainInteraction::Dissociatives]]''' - Huperzine A has an antagonistic effect on NMDA receptors and may enhance the dissociative effects of these dissociative agents{{DangerousInteractions/Intro}}
{{DangerousInteractions/Intro}}
==Potentiation of dissociatives==
==Potentiation of dissociatives==
Due to the ability of Huperzine A to antagonize NMDA receptors, it may potentiate the effects of dissociative compounds such as DXM, MXE, or Ketamine.
Due to the ability of Huperzine A to antagonize NMDA receptors, it may potentiate the effects of dissociative compounds such as DXM, MXE, or Ketamine.

Latest revision as of 16:06, 12 March 2025

This article is in the 'Talk' namespace because it is an unfinished draft. This section is used to host drafts for unpublished articles as well as discussions for published ones. If you'd like to use this area to discuss this draft, please do so in the 'Discussion' section at the very bottom of the page. This notice will be removed once this draft has been approved for publication by an administrator.


This page has not been fully approved by the PsychonautWiki administrators.

It may contain incorrect information, particularly with respect to dosage, duration, subjective effects, toxicity and other risks. It may also not meet PW style and grammar standards.

Summary sheet: Huperzine A
Huperzine A
Chemical Nomenclature
Common names Huperzine A、HupA
Substitutive name Huperzine A
Systematic name [[systematic name::5,9-Methanocycloocta[b]pyridin-2(1H)-one, 5-amino-11-ethylidene-5,6,9,10-tetrahydro-7-methyl-, (5R,9R,11E)-]]
Class Membership
Psychoactive class Nootropic / Oneirogen
Chemical class Others
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.



⇣ Oral
Dosage
Bioavailability 96% - 100%[citation needed]
Threshold 25 ug
Light 50 - 100 ug
Common 100 - 200 ug
Strong 200 - 450 ug
Heavy 450 ug +
Duration
Total 14 - 21 hours[1]
Onset x - y minutes
Come up x - y minutes
Peak 10 - 30 minutes[2]
Offset x - y hours
After effects x - y hours









DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

Interactions



For tips on how to properly format a substance article, please refer to this document: Content Style Guide - Substance


Huperzine A is a drug used to treat alzheimers and schizophrenia induced cognitive impairment. It is also used as a nootropic. It is a natural compound that occurs in multiple plants in the genus Huperzia and was first isolated and pharmacologically characterized by Chinese scientists in 1986 [3].

History and culture

This History and culture section is a stub.

As a result, it may contain incomplete or wrong information. You can help by expanding it.

Since initial discovery, scientists have been interested in huperzine A due to its pharmacological profile and potential anti-neurodegenerative properties [4]. Huperzine A has indeed been shown to indirectly influence several signaling pathways associated with neuroprotection, including neurotrophic factors or Wnt, and decreased amyloid beta accumulation in vivo.[5]. Besides its popularity in biomedical research, huperzine A is also commonly sold as a supplement for its ability to improve cognitive function. However, some placebo controled studies indicate low efficiancy [6].

Among psychonauts, huperzine A has also found its popularity as a dream potentiator and inducer of lucid dreams, similar to the less available galantamine [7]

Chemistry

This chemistry section is incomplete.

You can help by adding to it.

Huperzine A is a polycyclic sesquiterpene alkaloid with molecular formula of C15H18N2O [8]. Its biosynthesis is not well researched and likely involves both precursors of isoprenoids and alkaloids [9]. Multiple total syntheses have also been performed [10].

Pharmacology

This pharmacology section is incomplete.

You can help by adding to it.

Huperzine A is a reversible acetylcholinesterase inhibitor and NMDA receptor antagonist.

Subjective effects

 This subjective effects section is a stub.

As such, it is still in progress and may contain incomplete or wrong information.

You can help by expanding or correcting it.

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

Physical effects

Visual effects

  • If applicable, a brief paragraph summary of the substance's visual effects may be included here. You may select visual effects to add below here.

    Enhancements

    Distortions

    • Visual acuity supression - Typically at higher doses, huperzine a can cause blurred vision. This is likely due to its activity as an NMDA antagonist.

    '

Cognitive effects

Experience reports

There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:

Toxicity and harm potential

This toxicity and harm potential section is a stub.

As a result, it may contain incomplete or even dangerously wrong information! You can help by expanding upon or correcting it.
Note: Always conduct independent research and use harm reduction practices if using this substance.

It is strongly recommended that one use harm reduction practices when using this substance.

Lethal dosage

The exact lethal dosage of Huperzine A in humans is not well-documented. However, it is known to have a wide margin of safety and is generally considered non-toxic even at doses 50-100 times the therapeutic dose.[11]

Tolerance and addiction potential

Huperzine A is not known to be not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating.

Huperzine A does not seem to build up an immediate tolerance, and, due to its long half life (10-14 hours), becomes stronger with prolonged use. Caution should be taken when using Huperzine A for extended periods longer than two weeks. Huperzine A presents cross-tolerance with no other known compounds, meaning that after the consumption of Huperzine A all other psychoactive compounds will not have a reduced effect.

Dangerous interactions

This dangerous interactions section is a stub.

As such, it may contain incomplete or invalid information. You can help by expanding upon or correcting it.

  • Acetylcholinesterase inhibitors - Huperzine A may result in a cholinergic crisis when combined with other potent acetylcholinesterase inhibitors. Caution should also be exercised when combining Huperzine

A with caffeine or nicotine.

  • Dissociatives - Huperzine A has an antagonistic effect on NMDA receptors and may enhance the dissociative effects of these dissociative agentsWarning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

Potentiation of dissociatives

Due to the ability of Huperzine A to antagonize NMDA receptors, it may potentiate the effects of dissociative compounds such as DXM, MXE, or Ketamine.

This legality section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

See also

Literature

  • APA formatted reference

Please see the citation formatting guide if you need assistance properly formatting citations.

References

  1. ↑ 石杉碱甲胶囊说明书
  2. ↑ 链接文本，附加文本。
  3. ↑ Wang YE, Yue DX, Tang XC. [Anti-cholinesterase activity of huperzine A]. Zhongguo Yao Li Xue Bao. 1986 Mar;7(2):110-3. Chinese. PMID: 2946143.
  4. ↑ Yang G, Wang Y, Tian J, Liu JP. Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials. PLoS One. 2013 Sep 23;8(9):e74916. doi: 10.1371/journal.pone.0074916. PMID: 24086396; PMCID: PMC3781107.
  5. ↑ Friedli MJ, Inestrosa NC. Huperzine A and Its Neuroprotective Molecular Signaling in Alzheimer's Disease. Molecules. 2021 Oct 29;26(21):6531. doi: 10.3390/molecules26216531. PMID: 34770940; PMCID: PMC8587556.
  6. ↑ Wessinger CM, Inman CL, Weinstock J, Weiss EP. Effect of Huperzine A on Cognitive Function and Perception of Effort during Exercise: A Randomized Double-Blind Crossover Trial. Int J Exerc Sci. 2021 Aug 1;14(2):727-741. PMID: 34567353; PMCID: PMC8439683.
  7. ↑ https://www.world-of-lucid-dreaming.com/lucid-dream-pills.html
  8. ↑ National Center for Biotechnology Information (2023). PubChem Compound Summary for CID 854026, Huperzine A. Retrieved November 21, 2023 from https://pubchem.ncbi.nlm.nih.gov/compound/854026.
  9. ↑ Li X, Li W, Tian P, Tan T. Delineating biosynthesis of Huperzine A, A plant-derived medicine for the treatment of Alzheimer's disease. Biotechnol Adv. 2022 Nov;60:108026. doi: 10.1016/j.biotechadv.2022.108026. Epub 2022 Jul 30. PMID: 35914626.
  10. ↑ Total Synthesis of (−)-Huperzine A Takahiro Koshiba, Satoshi Yokoshima, and Tohru Fukuyama Organic Letters 2009 11 (22), 5354-5356 DOI: 10.1021/ol9022408
  11. ↑ Review of the value of huperzine as pretreatment of organophosphate poisoning，Review of the value of huperzine as pretreatment of organophosphate poisoning.
Retrieved from "https://psy.st/index.php?title=Talk:Huperzine_A&oldid=491451"